Clinical Trials Browser

Interventional × Has results × Omeprazole × Clear all

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

348 enrolled 15 charts

Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT03267680 2025-04-13

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Phase 2 Terminated

10 enrolled 19 charts

Gynecologic

Uterine Cervical Dysplasia

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1 Completed

56 enrolled 158 charts

Dermatologic

Melanoma

NCT02609386 2024-01-30

INSPIRE

Phase 2 Completed

105 enrolled 17 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms

NCT03531762 2023-07-28

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Phase 1 Completed

12 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03028103 2023-06-26

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Phase 1 Completed

32 enrolled 30 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02595372 2021-12-15

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

Phase 2 Completed

42 enrolled 14 charts

Breast

Breast Neoplasms

NCT00210470 2020-12-11

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

Phase 2 Completed

27 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms

NCT02500641 2019-06-21

FORWARD

Phase 4 Completed

196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT01093755 2016-03-17

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

Phase 4 Completed

30 enrolled 12 charts

Gastrointestinal

Barrett Esophagus, Inflammation

NCT00942175 2012-02-03

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Phase 1 Completed

160 enrolled 16 charts

Gastrointestinal

Esophagitis, Peptic, Stomach Ulcer, Zollinger-Ellison Syndrome

Clinical Trials

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

INSPIRE

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

FORWARD

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.